Novartis (NVS) Misses Q3 EPS by 6c, Sales Miss Expectations, Offers Q4 Outlook
Tweet
Share
E-mailGet Alerts NVS Hot Sheet
Join SI Premium – FREE
Novartis (NYSE: NVS) reported Q3 EPS of $1.45, $0.06 worse than the analyst estimate of $1.51. Revenue for the quarter came in at $14.8 billion versus the consensus estimate of $15.09 billion.
Pharmaceuticals is expected to deliver sales growth in the low- to mid-single digits, with volume growth more than offsetting the impact of generic competition and price pressures. In the fourth quarter, Diovan, as expected, will lose exclusivity in Europe. Alcon sales are expected to increase at a mid- to high-single digit rate on a pro forma basis. Sandoz is expected to deliver high-single digit sales growth, with the impact of the annualization of sales and increased competition for enoxaparin expected to dampen fourth quarter sales growth.
Pharmaceuticals is expected to deliver sales growth in the low- to mid-single digits, with volume growth more than offsetting the impact of generic competition and price pressures. In the fourth quarter, Diovan, as expected, will lose exclusivity in Europe. Alcon sales are expected to increase at a mid- to high-single digit rate on a pro forma basis. Sandoz is expected to deliver high-single digit sales growth, with the impact of the annualization of sales and increased competition for enoxaparin expected to dampen fourth quarter sales growth.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c
- Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c
Create E-mail Alert Related Categories
EarningsRelated Entities
Alcon Acquired by NovartisSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
